A
Andrew Hantel
Researcher at Harvard University
Publications - 39
Citations - 985
Andrew Hantel is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 9, co-authored 29 publications receiving 734 citations. Previous affiliations of Andrew Hantel include MacLean Center for Clinical Medical Ethics & University of Chicago.
Papers
More filters
Journal ArticleDOI
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
John S. Welch,Allegra A. Petti,Christopher A. Miller,Catrina Fronick,Michelle O'Laughlin,Robert S. Fulton,Richard K. Wilson,Jack Baty,Eric J. Duncavage,Bevan Tandon,Yi-Shan Lee,Lukas D. Wartman,Geoffrey L. Uy,Armin Ghobadi,Michael H. Tomasson,Iskra Pusic,Rizwan Romee,Todd A. Fehniger,Keith Stockerl-Goldstein,Ravi Vij,Stephen T. Oh,Camille N. Abboud,Amanda F. Cashen,Mark A. Schroeder,Meagan A. Jacoby,Sharon Heath,Kierstin Luber,Megan Janke,Andrew Hantel,Niloufer Khan,Madina Sukhanova,Randall W. Knoebel,Wendy Stock,Timothy A. Graubert,Matthew J. Walter,Peter Westervelt,Daniel C. Link,John F. DiPersio,Timothy J. Ley +38 more
TL;DR: Patients with AML and MDS who had cytogenetic abnormalities associated with unfavorable risk, TP53 mutations, or both had favorable clinical responses and robust (but incomplete) mutation clearance after receiving serial 10-day courses of decitabine.
Journal ArticleDOI
Analysis of very elderly (≥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome.
Chadi Nabhan,Sonali M. Smith,Irene Helenowski,Erika Ramsdale,Benjamin Parsons,Reem Karmali,Josephine Feliciano,Britt Hanson,Scott E. Smith,June M. McKoy,Annette Larsen,Andrew Hantel,Stephanie A. Gregory,Andrew M. Evens +13 more
TL;DR: Multivariate regression analysis identified two key factors that predicted inferior PFS and OS for both NHL groups: lack of CR and loss of ADLs.
Journal ArticleDOI
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
TL;DR: Increasing use of regimens that include immune checkpoint inhibition require vigilant monitoring for immune-activating side effects as they can occasionally be life threatening, as in this case of HLH.
Journal ArticleDOI
A new family with a germline ANKRD26 mutation and predisposition to myeloid malignancies
Rafael Márquez,Andrew Hantel,Rachelle Lorenz,Barbara Neistadt,Jerry Wong,Jane E. Churpek,Nameer Al Mardini,Ismael Shaukat,Sandeep Gurbuxani,Jonathan L. Miller,Lucy A. Godley +10 more
TL;DR: A mother-daughter pair with life-long thrombocytopenia presented for consultation regarding their presumed diagnoses of autoimmune-based idiopathic thromBocytopenic purpura (ITP) and their extended family history of bleeding and myeloid malignancies, and consideration was given to known alleles associated with congenital thROMbocy topenia with predisposition to MDS/AML.
Journal ArticleDOI
Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia
Niloufer Khan,Andrew Hantel,Randall W. Knoebel,Andrew S. Artz,Richard A. Larson,Lucy A. Godley,Michael J. Thirman,Hongtao Liu,Jane E. Churpek,Darren King,Olatoyosi Odenike,Wendy Stock +11 more
TL;DR: Retrospective data support using 10-day treatment cycles of decitabine in patients with relapsed/refractory AML, particularly for those with secondary or therapy-related AML.